newsfilter
← Latest News
GlobeNewswire·

Cytek Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026

  • Cytek Biosciences (NASDAQ: CTKB) will report third-quarter 2026 financial results after market close on Wednesday, November 4, 2026.
  • Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on November 4, 2026, to discuss results & outlook.
  • A live audio webcast of the call will be available on the "Investors" section of investors.cytekbio.com.
  • Cytek is a cell analysis solutions company utilizing patented Full Spectrum Profiling™ (FSP®) technology to enable high-resolution, high-content analysis.
  • The company's product portfolio includes Aurora™, Northern Lights™, Aurora™ CS, Aurora™ Evo, Borealis™ systems, Orion™ reagent preparation system, ESP™ technology, Amnis® & Guava® brands, plus reagents, software, & services.
  • Cytek is headquartered in Fremont, California, with global offices & distribution channels.
  • Most Cytek products are for research use only, except the Northern Lights-CLC system & certain reagents approved for clinical use in China & the European Union.
  • Cytek distributes material information via its website, SEC filings, press releases, conference calls, webcasts, LinkedIn, & X accounts in compliance with Regulation FD.
  • Media inquiries should be directed to Stephanie Olsen at Lages & Associates.
  • Investor inquiries should be directed to Mark Meehan at Cytek Biosciences.